1453835-43-2
1453835-43-2 structure
- Name: LLP3
- Chemical Name: LLP-3
- CAS Number: 1453835-43-2
- Molecular Formula: C32H23ClN2O4
- Molecular Weight: 534.989
- Catalog: Signaling Pathways Apoptosis Survivin
- Create Date: 2021-05-06 15:04:48
- Modify Date: 2025-08-27 11:20:58
-
LLP-3 is a potent Survivin inhibitor that disrupts the Survivin-Ran interaction in cancer cells. LLP-3 can be used in the research of Glioblastoma multiforme (GBM)[1].
| Name | LLP-3 |
|---|---|
| Synonyms |
3-Pyridinecarbonitrile, 4-[3,5-bis(phenylmethoxy)phenyl]-6-(5-chloro-2-hydroxyphenyl)-1,2-dihydro-2-oxo-
LLP-3 4-[3,5-Bis(benzyloxy)phenyl]-6-(5-chloro-2-hydroxyphenyl)-2-oxo-1,2-dihydro-3-pyridinecarbonitrile |
| Description | LLP-3 is a potent Survivin inhibitor that disrupts the Survivin-Ran interaction in cancer cells. LLP-3 can be used in the research of Glioblastoma multiforme (GBM)[1]. |
|---|---|
| Related Catalog | |
| Target |
Survivin[1] |
| In Vitro | LLP-3 (20 μM, 24 h) impaires the binding of Survivin to Smac/DIABLO (proapoptotic protein), without affecting the interaction of Survivin with other chromosomal passenger complex (CPC) proteins[1]. LLP-3 (20 μM, 24 h) decreases the Survivin-Ran interaction in U87 cells[1]. LLP-3 (20 μM, 24 h) arrests cell in G0-G1 phase and subsequent tumor cell death[1]. LLP-3 (20 μM, 24 h) triggers caspase-dependent apoptosis in HT1080 cells[1]. LLP-3 (0-100 μM, 72 h) inhibits tumor cells survival by p53-mediated inhibition[1]. Cell Viability Assay[1] Cell Line: U87E6, U87MG cell Concentration: 0-100 μM Incubation Time: 72 h Result: Inhibited tumor cells survival with IC50 values of 13.6 μM (U87E6) and 38.1 μM (U87MG). Cell Cycle Analysis[1] Cell Line: U87 cells Concentration: 20 μM Incubation Time: 24 h Result: Reduced the proportions of cells in the S and G2-M phases (from 9% to 5%, and from 25% to 17%, respectively). Increased G0-G1 cell population (from 60% to 74%). Immunofluorescence[1] Cell Line: U87, HT1080 cells Concentration: 40 μM Incubation Time: 24 h Result: Weakened the colocalization of TPX2 with the acetylated α-tubulin. |
| In Vivo | LLP-3 (intraperitoneal injection, 25 mg/kg, for 10 days) prolongs survival of GBM sphere-derived tumor mice[1]. Animal Model: GBM sphere-derived tumor models (GBM83 and 1600)[1] Dosage: 25 mg/kg Administration: Intraperitoneal injection, for 10 days (days 10–14 and days 17–21) Result: Prolonged the survival of tumor-burden mice without exhibiting any lethality of mice until day 35. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 787.1±60.0 °C at 760 mmHg |
| Molecular Formula | C32H23ClN2O4 |
| Molecular Weight | 534.989 |
| Flash Point | 429.8±32.9 °C |
| Exact Mass | 534.134644 |
| LogP | 7.62 |
| Vapour Pressure | 0.0±2.8 mmHg at 25°C |
| Index of Refraction | 1.704 |